Use of an LCP Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Cliniciansdoi:10.1681/ASN.20233411S11032dAlexander C. WisemanPorter Adventist Hospital, Denver, CO;Suphamai BunnapradistUniversity of California Los Angeles David Geffen School of Medicine, Los Angeles, CA...
tacrolimus twice-daily (Tac BID). This pooled analysis of two phase 3 randomized, controlled trials, including 861 (LCPT N = 428; Tac BID N = 433; 38% of patients were stable KTR, and 62% were de novo KTR) patients, examined the efficacy of LCPT in KTR subgroups ...
To prevent rejection kidney transplant recipients are treated with immunosuppressive drugs, like tacrolimus. The dosage needed to reach therapeutic trough levels of tacrolimus greatly varies between patients. Currently, there are two tacrolimus extended-release variants on the market. Tacrolimus-extended ...
Real-World Administration of Once-Daily MeltDose Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantationdoi:10.3390/jcm10010124Katharina WilluweitAlexandra FreyAnne Hoerster...
Budde K, Bunnapradist S, Grinyó JM et al (2014) Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transpl 14(12):2796–2806. : 10.1111/ajt....